ReviewPost-screenMicrofluidic models for adoptive cell-mediated cancer immunotherapies

- 3D microfluidic tumour models are effective in screening for T cell therapeutic strategies.
- 3D microfluidics can decrease the cost and time for optimising T cell immunotherapy.
- Microfluidic devices enable patient-specific preclinical tests of T cell therapies.

Current adoptive T cell therapies have shown promising results in clinical trials but need further development as an effective cancer treatment. Here, we discuss how 3D microfluidic tumour models mimicking the tumour microenvironment could help in testing T cell immunotherapies by assessing engineered T cells and identifying combinatorial therapy to improve therapeutic efficacy. We propose that 3D microfluidic systems can be used to screen different patient-specific treatments, thereby reducing the burden of in vivo testing and facilitating the rapid translation of successful T cell cancer immunotherapies to the clinic.